BioLargo (BLGO) Competitors

$0.15 0.00 (-2.10%)

As of 03:55 PM Eastern

BLGO vs. AMTX, SAFX, CBUS, ARQ, and FSI

Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include Aemetis (AMTX), XCF Global Capital (SAFX), Cibus (CBUS), ARQ (ARQ), and Flexible Solutions International (FSI). These companies are all part of the "chemicals" industry.

How does BioLargo compare to Aemetis?

BioLargo (NASDAQ:BLGO) and Aemetis (NASDAQ:AMTX) are both small-cap chemicals companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

: 0.0% of BioLargo shares are held by institutional investors. Comparatively, 27.0% of Aemetis shares are held by institutional investors. 19.3% of BioLargo shares are held by insiders. Comparatively, 13.0% of Aemetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Aemetis has a consensus price target of $8.58, suggesting a potential upside of 134.52%. Given Aemetis' stronger consensus rating and higher possible upside, analysts plainly believe Aemetis is more favorable than BioLargo.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Aemetis
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: BioLargo has higher earnings, but lower revenue than Aemetis. BioLargo is trading at a lower price-to-earnings ratio than Aemetis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLargo $12.23M 4.01 -$3.50M -$0.03 N/A
Aemetis $197.63M 1.26 -$77M -$1.33 N/A
: In the previous week, BioLargo had 2 more articles in the media than Aemetis. MarketBeat recorded 4 mentions for BioLargo and 2 mentions for Aemetis. BioLargo's average media sentiment score of 0.20 beat Aemetis' score of 0.00 indicating that BioLargo is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLargo
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aemetis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: BioLargo has a net margin of -11.45% compared to Aemetis' net margin of -38.96%. Aemetis' return on equity of 0.00% beat BioLargo's return on equity.
Company Net Margins Return on Equity Return on Assets
BioLargo -11.45% -39.90% -22.06%
Aemetis -38.96% N/A -35.53%
: BioLargo has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Aemetis has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aemetis	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLargo	$12.23M	4.01	-$3.50M	-$0.03	N/A
Aemetis	$197.63M	1.26	-$77M	-$1.33	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLargo	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aemetis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
BioLargo	-11.45%	-39.90%	-22.06%
Aemetis	-38.96%	N/A	-35.53%

Summary

BioLargo and Aemetis tied by winning 8 of the 16 factors compared between the two stocks.

How does BioLargo compare to XCF Global Capital?

XCF Global Capital (NASDAQ:SAFX) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

: 52.3% of XCF Global Capital shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 0.1% of XCF Global Capital shares are owned by company insiders. Comparatively, 19.3% of BioLargo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: XCF Global Capital presently has a consensus price target of $0.40, suggesting a potential downside of 14.26%. Given XCF Global Capital's stronger consensus rating and higher probable upside, analysts plainly believe XCF Global Capital is more favorable than BioLargo.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XCF Global Capital
1 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.67
BioLargo
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: XCF Global Capital has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than XCF Global Capital, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XCF Global Capital $20.82M 6.17 $74.02M -$0.61 N/A
BioLargo $12.23M 4.01 -$3.50M -$0.03 N/A
: In the previous week, XCF Global Capital had 1 more articles in the media than BioLargo. MarketBeat recorded 5 mentions for XCF Global Capital and 4 mentions for BioLargo. XCF Global Capital's average media sentiment score of 0.27 beat BioLargo's score of 0.20 indicating that XCF Global Capital is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XCF Global Capital
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLargo
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: XCF Global Capital has a net margin of 0.00% compared to BioLargo's net margin of -11.45%. XCF Global Capital's return on equity of 0.00% beat BioLargo's return on equity.
Company Net Margins Return on Equity Return on Assets
XCF Global Capital N/A N/A N/A
BioLargo -11.45% -39.90% -22.06%
: XCF Global Capital has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Comparatively, BioLargo has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XCF Global Capital	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XCF Global Capital	$20.82M	6.17	$74.02M	-$0.61	N/A
BioLargo	$12.23M	4.01	-$3.50M	-$0.03	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XCF Global Capital	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLargo	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
XCF Global Capital	N/A	N/A	N/A
BioLargo	-11.45%	-39.90%	-22.06%

Summary

XCF Global Capital beats BioLargo on 12 of the 15 factors compared between the two stocks.

How does BioLargo compare to Cibus?

Cibus (NASDAQ:CBUS) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

: BioLargo has a net margin of -11.45% compared to Cibus' net margin of -3,492.30%. BioLargo's return on equity of -39.90% beat Cibus' return on equity.
Company Net Margins Return on Equity Return on Assets
Cibus -3,492.30% -174.58% -29.48%
BioLargo -11.45% -39.90% -22.06%
: BioLargo has higher revenue and earnings than Cibus. BioLargo is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cibus $3.64M 32.30 -$127.08M -$2.98 N/A
BioLargo $12.23M 4.01 -$3.50M -$0.03 N/A
: 33.8% of Cibus shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 49.4% of Cibus shares are owned by company insiders. Comparatively, 19.3% of BioLargo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: In the previous week, Cibus had 1 more articles in the media than BioLargo. MarketBeat recorded 5 mentions for Cibus and 4 mentions for BioLargo. Cibus' average media sentiment score of 0.48 beat BioLargo's score of 0.20 indicating that Cibus is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLargo
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 484.42%. Given Cibus' stronger consensus rating and higher probable upside, analysts plainly believe Cibus is more favorable than BioLargo.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
BioLargo
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Cibus has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, BioLargo has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-3,492.30%	-174.58%	-29.48%
BioLargo	-11.45%	-39.90%	-22.06%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	32.30	-$127.08M	-$2.98	N/A
BioLargo	$12.23M	4.01	-$3.50M	-$0.03	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cibus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLargo	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cibus beats BioLargo on 10 of the 16 factors compared between the two stocks.

How does BioLargo compare to ARQ?

ARQ (NASDAQ:ARQ) and BioLargo (NASDAQ:BLGO) are both small-cap chemicals companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

: BioLargo has a net margin of -11.45% compared to ARQ's net margin of -43.72%. ARQ's return on equity of -1.99% beat BioLargo's return on equity.
Company Net Margins Return on Equity Return on Assets
ARQ -43.72% -1.99% -1.52%
BioLargo -11.45% -39.90% -22.06%
: BioLargo has lower revenue, but higher earnings than ARQ. BioLargo is trading at a lower price-to-earnings ratio than ARQ, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ARQ $120.34M 0.84 -$52.61M -$1.27 N/A
BioLargo $12.23M 4.01 -$3.50M -$0.03 N/A
: 18.5% of ARQ shares are owned by institutional investors. Comparatively, 0.0% of BioLargo shares are owned by institutional investors. 23.9% of ARQ shares are owned by insiders. Comparatively, 19.3% of BioLargo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, BioLargo had 1 more articles in the media than ARQ. MarketBeat recorded 4 mentions for BioLargo and 3 mentions for ARQ. ARQ's average media sentiment score of 0.48 beat BioLargo's score of 0.20 indicating that ARQ is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ARQ
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLargo
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: ARQ presently has a consensus price target of $7.50, suggesting a potential upside of 216.46%. Given ARQ's stronger consensus rating and higher possible upside, equities analysts plainly believe ARQ is more favorable than BioLargo.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ARQ
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.60
BioLargo
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: ARQ has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, BioLargo has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
ARQ	-43.72%	-1.99%	-1.52%
BioLargo	-11.45%	-39.90%	-22.06%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARQ	$120.34M	0.84	-$52.61M	-$1.27	N/A
BioLargo	$12.23M	4.01	-$3.50M	-$0.03	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARQ	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLargo	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARQ	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

ARQ beats BioLargo on 12 of the 17 factors compared between the two stocks.

How does BioLargo compare to Flexible Solutions International?

BioLargo (NASDAQ:BLGO) and Flexible Solutions International (NYSE:FSI) are both small-cap chemicals companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

: BioLargo has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Flexible Solutions International has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
: In the previous week, BioLargo had 3 more articles in the media than Flexible Solutions International. MarketBeat recorded 4 mentions for BioLargo and 1 mentions for Flexible Solutions International. Flexible Solutions International's average media sentiment score of 0.87 beat BioLargo's score of 0.20 indicating that Flexible Solutions International is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLargo
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Flexible Solutions International
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Flexible Solutions International
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.50
: 0.0% of BioLargo shares are held by institutional investors. Comparatively, 54.3% of Flexible Solutions International shares are held by institutional investors. 19.3% of BioLargo shares are held by insiders. Comparatively, 35.8% of Flexible Solutions International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Flexible Solutions International has a net margin of 10.80% compared to BioLargo's net margin of -11.45%. Flexible Solutions International's return on equity of 10.61% beat BioLargo's return on equity.
Company Net Margins Return on Equity Return on Assets
BioLargo -11.45% -39.90% -22.06%
Flexible Solutions International 10.80% 10.61% 7.32%
: Flexible Solutions International has higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Flexible Solutions International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLargo $12.23M 4.01 -$3.50M -$0.03 N/A
Flexible Solutions International $38.52M 2.00 $2.78M $0.06 100.83

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLargo	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Flexible Solutions International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Flexible Solutions International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
BioLargo	-11.45%	-39.90%	-22.06%
Flexible Solutions International	10.80%	10.61%	7.32%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLargo	$12.23M	4.01	-$3.50M	-$0.03	N/A
Flexible Solutions International	$38.52M	2.00	$2.78M	$0.06	100.83

Summary

Flexible Solutions International beats BioLargo on 13 of the 15 factors compared between the two stocks.

Get BioLargo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLGO vs. The Competition

Export

Metric	BioLargo	Chemicals & allied products Industry	Construction Sector	NASDAQ Exchange
Market Cap	$49.05M	$7.94B	$9.73B	$11.77B
Dividend Yield	N/A	1.09%	1.82%	5.26%
P/E Ratio	-15.36	N/A	19.13	27.07
Price / Sales	4.01	3.09	4.09	73.47
Price / Cash	N/A	270.17	18.05	53.90
Price / Book	15.36	9.12	7.90	6.69
Net Income	-$3.50M	$659.84M	$558.29M	$332.64M
7 Day Performance	-0.90%	-0.30%	3.35%	2.01%
1 Month Performance	2.74%	1.05%	9.98%	9.19%
1 Year Performance	-29.18%	-8.98%	27.43%	39.59%

BioLargo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLGO BioLargo	N/A	$0.15 -2.1%	N/A	N/A	$49.05M	$12.23M	N/A	30	News Coverage Gap Up
AMTX Aemetis	1.5857 of 5 stars	$2.74 +4.6%	$8.58 +213.3%	N/A	$178.54M	$207.98M	N/A	160	Upcoming Earnings
SAFX XCF Global Capital	0.8861 of 5 stars	$0.37 -6.8%	$0.40 +6.9%	N/A	$110.57M	$20.82M	N/A	N/A	News Coverage Gap Down
CBUS Cibus	2.0007 of 5 stars	$1.49 flat	$9.00 +504.0%	N/A	$103.10M	$3.64M	N/A	48	News Coverage Upcoming Earnings
ARQ ARQ	4.7644 of 5 stars	$2.23 +0.5%	$7.50 +236.3%	N/A	$95.18M	$120.34M	N/A	140	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLGO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLargo (BLGO) Competitors